Doctoral Programme in Drug Research

The application deadline is 2026-09-15.

The Doctoral Programme in Drug Research (DPDR) at the University of Helsinki is a multidisciplinary program that spans the full life cycle of drug development, from identifying novel drug targets through to pharmacovigilance. Research areas include brain diseases, fundamental neuroscience, cancer medicine, and antibiotic resistance. Pharmaceutical and biopharmaceutical research in the program covers small molecule drug design, medicinal chemistry, biological drugs such as antibodies, proteins, peptides, and viral vectors, bioactivity screening, drug formulation, nanomedicines, pharmacokinetics, pharmacodynamics, drug preclinical efficacy and safety, and novel analytical methods including process analytical technologies. From a patient and public health perspective, the program also addresses drug interactions, pharmacogenetics, clinical pharmacology, pharmacoepidemiology, clinical pharmacy, social pharmacy, pharmacoeconomics, toxicology, and veterinary drug research. The main component of doctoral education is research conducted in research groups under the guidance of supervisors, complemented by discipline-specific coursework. The program runs for four years, starting September 2026, and addresses both fundamental and applied research relevant to societal challenges. The program is based at the University of Helsinki in Helsinki, Finland.